Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.70
INFI's Cash to Debt is ranked lower than
61% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. INFI: 5.70 )
Ranked among companies with meaningful Cash to Debt only.
INFI' s Cash to Debt Range Over the Past 10 Years
Min: 0.28  Med: 493.15 Max: 13254
Current: 5.7
0.28
13254
Equity to Asset 0.63
INFI's Equity to Asset is ranked lower than
55% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INFI: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
INFI' s Equity to Asset Range Over the Past 10 Years
Min: -0.03  Med: 0.65 Max: 0.94
Current: 0.63
-0.03
0.94
F-Score: 3
Z-Score: -4.87
M-Score: -4.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -39.50
INFI's Operating margin (%) is ranked higher than
58% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. INFI: -39.50 )
Ranked among companies with meaningful Operating margin (%) only.
INFI' s Operating margin (%) Range Over the Past 10 Years
Min: -144.7  Med: -94.93 Max: 22.94
Current: -39.5
-144.7
22.94
Net-margin (%) -39.11
INFI's Net-margin (%) is ranked higher than
57% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. INFI: -39.11 )
Ranked among companies with meaningful Net-margin (%) only.
INFI' s Net-margin (%) Range Over the Past 10 Years
Min: -153.81  Med: -68.67 Max: 28.35
Current: -39.11
-153.81
28.35
ROE (%) -46.05
INFI's ROE (%) is ranked lower than
58% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. INFI: -46.05 )
Ranked among companies with meaningful ROE (%) only.
INFI' s ROE (%) Range Over the Past 10 Years
Min: -123.36  Med: -41.36 Max: 27.59
Current: -46.05
-123.36
27.59
ROA (%) -19.29
INFI's ROA (%) is ranked higher than
59% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. INFI: -19.29 )
Ranked among companies with meaningful ROA (%) only.
INFI' s ROA (%) Range Over the Past 10 Years
Min: -44.77  Med: -27.61 Max: 16.29
Current: -19.29
-44.77
16.29
ROC (Joel Greenblatt) (%) -114.41
INFI's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. INFI: -114.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INFI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3134.63  Med: -554.64 Max: 418.86
Current: -114.41
-3134.63
418.86
Revenue Growth (3Y)(%) 14.40
INFI's Revenue Growth (3Y)(%) is ranked higher than
66% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. INFI: 14.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INFI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -2.7 Max: 154.4
Current: 14.4
-100
154.4
EBITDA Growth (3Y)(%) 16.80
INFI's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. INFI: 16.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INFI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.6  Med: 12.2 Max: 261
Current: 16.8
-64.6
261
EPS Growth (3Y)(%) 15.50
INFI's EPS Growth (3Y)(%) is ranked higher than
73% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. INFI: 15.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INFI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64  Med: 12.35 Max: 116
Current: 15.5
-64
116
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

INFI Guru Trades in Q4 2015

Steven Cohen 191,400 sh (New)
Samuel Isaly 678,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 158,100 sh (-81.98%)
» More
Q1 2016

INFI Guru Trades in Q1 2016

Paul Tudor Jones 59,600 sh (New)
Steven Cohen Sold Out
Jim Simons 12,300 sh (-92.22%)
Samuel Isaly 654,534 sh (-3.46%)
» More
Q2 2016

INFI Guru Trades in Q2 2016

Jim Simons 749,700 sh (+5995.12%)
Paul Tudor Jones 277,600 sh (+365.77%)
Samuel Isaly Sold Out
» More
Q3 2016

INFI Guru Trades in Q3 2016

Jim Simons 1,860,900 sh (+148.22%)
Paul Tudor Jones 19,798 sh (-92.87%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:VCEL, NAS:EBIO, OTCPK:COTQF, NAS:HTBX, AMEX:NBY, NAS:NTEC, NAS:NWBO, OTCPK:IMMVF, OTCPK:KBIO, OTCPK:MTFBF, NAS:TRIL, NAS:PBMD, NAS:PIRS, NAS:AVIR, NAS:SBPH, NAS:AEGR, NAS:KMPH, AMEX:ATNM, OTCPK:DYAI, NAS:CAPR » details
Traded in other countries:I3F.Germany,
Infinity Pharmaceuticals Inc is a biopharmaceutical company engaged in discovering, developing & delivering medicines to people with difficult-to-treat diseases. Its primary product candidate is duvelisib, also known as IPI-145, an oral inhibitor.

Infinity Pharmaceuticals Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998, it changed its name to Discovery Partners International, Inc., or DPI. In July 2000, it reincorporated in Delaware. On September 12, 2006, DPI completed a merger with the Company, pursuant to which a wholly-owned subsidiary of DPI merged with and into the Company. In addition, it changed its corporate name from Discovery Partners International, Inc. to Infinity Pharmaceuticals, Inc. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to patients with difficult-to-treat diseases. Its product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which is being evaluated for the treatment of hematologic malignancies, or blood cancers. The Company's product candidates, duvelisib and IPI-549 include DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Advanced Hematologic Malignancies consists of Duvelisib + Venetoclax, IPI-549: PI3K Gamma-Selective Inhibitor. As part of the DUETTS program in lymphoma, it is conducting DYNAMO, a Phase 2, open-label, single-arm monotherapy study evaluating the safety and efficacy of duvelisib dosed at 25 mg twice daily in 129 patients with iNHL. The FDA has granted orphan drug designation to duvelisib for the potential treatment of follicular lymphoma, and has granted fast track designation to the investigation of duvelisib for the treatment of patients with follicular lymphoma who have received at least two prior therapies. The Company has eight issued or allowed U.S. patents related to its duvelisib program, which expire on various dates between 2029 and 2032, excluding any patent term extension. It has three issued or allowed U.S. patents related to its PI3K gamma program, which expire on various dates between 2033 and 2034, excluding any patent term extension. In addition, it has approximately 275 patents and patent applications pending related to its PI3K programs.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 1.54
INFI's Price/Owner Earnings (ttm) is ranked higher than
96% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. INFI: 1.54 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
INFI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.02  Med: 10.58 Max: 154.41
Current: 1.54
1.02
154.41
P/B 0.68
INFI's P/B is ranked higher than
96% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. INFI: 0.68 )
Ranked among companies with meaningful P/B only.
INFI' s P/B Range Over the Past 10 Years
Min: 0.45  Med: 3.17 Max: 51.43
Current: 0.68
0.45
51.43
P/S 2.51
INFI's P/S is ranked higher than
85% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. INFI: 2.51 )
Ranked among companies with meaningful P/S only.
INFI' s P/S Range Over the Past 10 Years
Min: 0.55  Med: 3.85 Max: 60.95
Current: 2.51
0.55
60.95
EV-to-EBIT 0.48
INFI's EV-to-EBIT is ranked higher than
88% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. INFI: 0.48 )
Ranked among companies with meaningful EV-to-EBIT only.
INFI' s EV-to-EBIT Range Over the Past 10 Years
Min: -265.5  Med: -2.6 Max: 10.9
Current: 0.48
-265.5
10.9
EV-to-EBITDA 0.50
INFI's EV-to-EBITDA is ranked higher than
89% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. INFI: 0.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
INFI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -91.3  Med: -2.65 Max: 782
Current: 0.5
-91.3
782
Current Ratio 4.77
INFI's Current Ratio is ranked higher than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. INFI: 4.77 )
Ranked among companies with meaningful Current Ratio only.
INFI' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 8.37 Max: 17.81
Current: 4.77
0.64
17.81
Quick Ratio 4.77
INFI's Quick Ratio is ranked higher than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. INFI: 4.77 )
Ranked among companies with meaningful Quick Ratio only.
INFI' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 8.37 Max: 17.81
Current: 4.77
0.41
17.81
Days Sales Outstanding 5.50
INFI's Days Sales Outstanding is ranked higher than
90% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. INFI: 5.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
INFI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.18  Med: 2.7 Max: 831.54
Current: 5.5
0.18
831.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.30
INFI's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. INFI: -1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INFI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.7  Med: -16.2 Max: -0.8
Current: -1.3
-178.7
-0.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.12
INFI's Price/Net Cash is ranked higher than
97% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. INFI: 1.12 )
Ranked among companies with meaningful Price/Net Cash only.
INFI' s Price/Net Cash Range Over the Past 10 Years
Min: 0.85  Med: 2.87 Max: 38.43
Current: 1.12
0.85
38.43
Price/Net Current Asset Value 0.95
INFI's Price/Net Current Asset Value is ranked higher than
97% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. INFI: 0.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INFI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.74  Med: 2.69 Max: 398.67
Current: 0.95
0.74
398.67
Price/Tangible Book 0.68
INFI's Price/Tangible Book is ranked higher than
97% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. INFI: 0.68 )
Ranked among companies with meaningful Price/Tangible Book only.
INFI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.55  Med: 2.33 Max: 46.18
Current: 0.68
0.55
46.18
Price/Median PS Value 0.65
INFI's Price/Median PS Value is ranked higher than
77% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. INFI: 0.65 )
Ranked among companies with meaningful Price/Median PS Value only.
INFI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 0.67 Max: 15.54
Current: 0.65
0.14
15.54
Earnings Yield (Greenblatt) (%) 205.76
INFI's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. INFI: 205.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INFI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 9.2  Med: 74.5 Max: 857.3
Current: 205.76
9.2
857.3

More Statistics

Revenue (TTM) (Mil) $118.5
EPS (TTM) $ -0.96
Beta2.31
Short Percentage of Float6.61%
52-Week Range $0.84 - 8.19
Shares Outstanding (Mil)49.73

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 19 90 55
EPS ($) -1.49 -0.93 -0.76 -0.76
EPS w/o NRI ($) -1.49 -0.93 -0.76 -0.76
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for INFI

Headlines

Articles On GuruFocus.com
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
INFINITY PHARMACEUTICALS, INC. Financials Nov 17 2016
Infinis plc announces second quarter results for year ending 31.03.17 £350m 7% Senior Notes due... Nov 16 2016
Infinity (INFI) Reports Narrower-than-Expected Loss in Q3 Nov 11 2016
Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up On Opdivo... Nov 10 2016
Blog Coverage Bristol-Myers Squibb and Infinity Pharma Collaborate for Clinical Trials to Test... Nov 10 2016
Edited Transcript of INFI earnings conference call or presentation 9-Nov-16 9:30pm GMT Nov 09 2016
Infinity reports 3Q loss Nov 09 2016
Infinity reports 3Q loss Nov 09 2016
Infinity Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Nov 09 2016
Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results Nov 09 2016
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 09 2016
Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results Nov 09 2016
INFINITY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
Infinity Announces Second Publication on PI3K-Gamma in Nature Nov 09 2016
Infinity Announces Second Publication on PI3K-Gamma in Nature Nov 09 2016
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo... Nov 09 2016
Q3 2016 Infinity Pharmaceuticals Inc Earnings Release - After Market Close Nov 09 2016
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo... Nov 09 2016
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo... Nov 09 2016
Endo (ENDP) Q3 Earnings & Revenues Beat; View Intact Nov 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)